Fig. 1 · Structure
Documents & Downloads
Trastuzumab rezetecan
HER2-Targeting ADC
Trastuzumab rezetecan is a HER2-targeting antibody-drug conjugate (ADC) designed to deliver cytotoxic agents specifically to HER2-expressing cells. This compound consists of a humanized anti-HER2 antibody linked to a cleavable peptide linker and the topoisomerase I inhibitor, Rezetecán. It demonstrates significant antitumor activity and is primarily utilized in research focused on HER2-positive breast cancer, providing valuable insights into targeted therapies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2924909-11-3 |
| Applications | HER2-Targeting ADC |
| Synonyms | SHR-A1811 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.